Literature DB >> 23467778

Hepatitis C virus (HCV)-related cryoglobulinemia: cryoglobulin type and anti-HCV profile.

Martha Minopetrou1, Emilia Hadziyannis, Melanie Deutsch, Maria Tampaki, Asimina Georgiadou, Eleni Dimopoulou, Dimitrios Vassilopoulos, John Koskinas.   

Abstract

Cryoglobulin characteristics in chronic hepatitis C (CHC) might be of importance for knowing more about the pathogenesis and treatment of the disease. We aimed to investigate the relationship between cryoglobulin types and their specificity against hepatitis C virus (HCV) antigenic epitopes in CHC patients. We analyzed samples from 43 patients with HCV-associated cryoglobulinemia, of whom 4 had concomitant lymphoma. Cryoglobulins were measured, purified, typed by immunofixation electrophoresis, and tested for IgG and IgM anti-HCV antibodies by immunoblot analysis and an enzyme-linked immunosorbent assay (ELISA). Clinical and other laboratory data were recorded. The median cryocrit level of the tested samples was 6%. Type I cryoglobulins were detected in 9.3% (4/43) of the cryoprecipitates, and type II cryoglobulins were detected in 48.8% (21/43) of the cryoprecipitates. IgM monoclonal protein, mainly IgM(κ), was found in 92% (23/25) of type I and II cryoprecipitates. Type III cryoglobulins were identified in 41.9% (18/43) of the patients and were associated with high blood serum IgG levels. In 81.3% (13/16) of type II and 92.3% (12/13) of type III cryoglobulins, there was IgG reactivity against the viral core region. Ninety-two percent and 32% of IgG anti-HCV core-positive cryoprecipitates had additional specificities against the NS3 and NS4 regions, respectively. Also, IgM anti-HCV antibodies were detected in 31% of the cryoprecipitates. In conclusion, all types of cryoglobulins were found in patients with HCV-associated cryoglobulinemia, with type II being the most frequently identified. Type III cryoglobulins were common and were associated with high serum IgG levels. HCV-related cryoglobulins demonstrated IgM, and particularly IgG, anti-HCV specificities, mainly against the core and NS3 epitopes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23467778      PMCID: PMC3647756          DOI: 10.1128/CVI.00720-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  43 in total

1.  Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma.

Authors:  E Zuckerman; T Zuckerman; A M Levine; D Douer; K Gutekunst; M Mizokami; D G Qian; M Velankar; B N Nathwani; T L Fong
Journal:  Ann Intern Med       Date:  1997-09-15       Impact factor: 25.391

Review 2.  Cryoglobulin evaluation: best practice?

Authors:  Ravishankar Sargur; Peter White; William Egner
Journal:  Ann Clin Biochem       Date:  2010-01       Impact factor: 2.057

3.  Risk of non-Hodgkin's lymphoma in patients with hepatitis C virus infection.

Authors:  M Ohsawa; N Shingu; H Miwa; H Yoshihara; M Kubo; H Tsukuma; H Teshima; M Hashimoto; K Aozasa
Journal:  Int J Cancer       Date:  1999-01-18       Impact factor: 7.396

Review 4.  Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations.

Authors:  Domenico Sansonno; Franco Dammacco
Journal:  Lancet Infect Dis       Date:  2005-04       Impact factor: 25.071

5.  Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia.

Authors:  D Sansonno; S De Vita; A R Iacobelli; V Cornacchiulo; M Boiocchi; F Dammacco
Journal:  J Immunol       Date:  1998-04-01       Impact factor: 5.422

6.  Hepatic lymphoid aggregates in chronic hepatitis C and mixed cryoglobulinemia.

Authors:  A Monteverde; M Ballarè; S Pileri
Journal:  Springer Semin Immunopathol       Date:  1997

7.  Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus.

Authors:  Thomas P Giordano; Louise Henderson; Ola Landgren; Elizabeth Y Chiao; Jennifer R Kramer; Hashem El-Serag; Eric A Engels
Journal:  JAMA       Date:  2007-05-09       Impact factor: 56.272

8.  Cryoglobulinemia in chronic hepatitis C virus infection: prevalence, clinical manifestations, response to interferon treatment and analysis of cryoprecipitates.

Authors:  H Hartmann; P Schott; F Polzien; S Mihm; A Uy; U Kaboth; I Pardowitz; G Ramadori
Journal:  Z Gastroenterol       Date:  1995-11       Impact factor: 2.000

9.  Fcgamma receptor-like activity of hepatitis C virus core protein.

Authors:  Patrick Maillard; Jean-Pierre Lavergne; Sophie Sibéril; Grazyna Faure; Farzin Roohvand; Stephane Petres; Jean Luc Teillaud; Agata Budkowska
Journal:  J Biol Chem       Date:  2003-11-10       Impact factor: 5.157

Review 10.  HCV proteins and immunoglobulin variable gene (IgV) subfamilies in HCV-induced type II mixed cryoglobulinemia: a concurrent pathogenetic role.

Authors:  Giuseppe Sautto; Nicasio Mancini; Laura Solforosi; Roberta A Diotti; Massimo Clementi; Roberto Burioni
Journal:  Clin Dev Immunol       Date:  2012-05-29
View more
  4 in total

Review 1.  Extrahepatic immune related manifestations in chronic hepatitis C virus infection.

Authors:  Maria Tampaki; John Koskinas
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

2.  Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Antonio Russo; Mariantonietta Pisaturo; Clarissa Camaioni; Roberta Astorri; Nicola Coppola
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Relationships between lymphomas linked to hepatitis C virus infection and their microenvironment.

Authors:  Antonino Carbone; Annunziata Gloghini
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

4.  Impact of Chronic Hepatitis C Virus Genotype 1b Infection on Triglyceride Concentration in Serum Lipoprotein Fractions.

Authors:  Tomohisa Nagano; Nobuyoshi Seki; Yoichi Tomita; Tomonori Sugita; Yuta Aida; Munenori Itagaki; Satoshi Sutoh; Hiroshi Abe; Akihito Tsubota; Yoshio Aizawa
Journal:  Int J Mol Sci       Date:  2015-08-31       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.